Unblocking Barriers of Access to Hepatitis C Treatment in China: Lessons Learned from Tianjin.

ABSTRACT:

Background

The high price is a critical barrier of access to new direct-anting-antiviral (DAA) therapies for hepatitis C for both the patients and the society. Many countries continue to face the challenge of financing such expensive medicines. Such examples include both high-income and middle-income countries. Existing evidence about the efforts of China to address this challenge is limited. To our knowledge, this is the first detailed description of a novel financing model and comprehensive analysis of its impact on patient financial burden of hepatitis C treatment in China.

Objective

To examine the evolution of approaches to navigating patients' barriers of access to DAA-based treatment of hepatitis C in Tianjin City, China.

Methods

Review of publicly available lit

SUBMITTER: Zhang P 

PROVIDER: S-EPMC7181951 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature